No, You Should Not Take Trelegy and Advair Together
Do not use Trelegy (fluticasone furoate/umeclidinium/vilanterol) and Advair (fluticasone propionate/salmeterol) concurrently—this combination results in dangerous duplication of both inhaled corticosteroids and long-acting beta-agonists, significantly increasing the risk of serious adverse effects without additional therapeutic benefit.
Why This Combination Is Contraindicated
Medication Component Overlap
Both medications contain:
- Inhaled corticosteroids (ICS): Trelegy contains fluticasone furoate; Advair contains fluticasone propionate
- Long-acting beta-agonists (LABA): Trelegy contains vilanterol; Advair contains salmeterol
Using both simultaneously creates:
- Double ICS exposure: Dramatically increases risk of systemic corticosteroid effects including adrenal suppression, immunosuppression, pneumonia (especially in COPD), bone density loss, and glaucoma 1
- Double LABA exposure: Heightens cardiovascular risks including tachycardia, arrhythmias, hypokalemia, and hyperglycemia 1
Specific Safety Concerns from FDA Labeling
The Trelegy label explicitly warns about:
- Increased pneumonia risk in COPD patients with ICS use 1
- Hypercorticism and adrenal suppression with excessive corticosteroid exposure 1
- Cardiovascular effects from beta-agonist therapy 1
- Paradoxical bronchospasm 1
Doubling these medication classes amplifies all these risks without improving outcomes.
The Correct Approach: Choose One Appropriate Therapy
If Currently on Advair and Considering Trelegy
Stop Advair completely before starting Trelegy. Trelegy is the superior choice if:
- The patient has COPD with exacerbation history (Trelegy adds umeclidinium, a long-acting muscarinic antagonist, providing triple therapy) 2
- Once-daily dosing would improve adherence versus Advair's twice-daily regimen
- The patient requires escalation from dual to triple therapy
If Currently on Trelegy
There is no clinical scenario where adding Advair provides benefit. Trelegy already contains:
- An ICS (fluticasone furoate)
- A LABA (vilanterol)
- A LAMA (umeclidinium)
This represents complete triple therapy coverage.
Evidence-Based Guidance
For COPD Patients
The 2023 Canadian Thoracic Society guidelines support single-inhaler triple therapy (SITT) like Trelegy for patients with exacerbation history 2. Real-world evidence demonstrates that FF/UMEC/VI (Trelegy) significantly reduces exacerbation rates and improves outcomes 3, 4, 5.
For Asthma Patients
If treating asthma, either Trelegy or Advair may be appropriate depending on disease severity, but never both simultaneously 6. The 2020 asthma guidelines support ICS/LABA combinations but do not endorse medication duplication 6.
Common Clinical Pitfalls to Avoid
- Transitioning between inhalers: Always discontinue the first medication before starting the second—do not overlap
- "Rescue" misconception: Neither Trelegy nor Advair is a rescue inhaler; patients need a separate short-acting bronchodilator (albuterol) for acute symptoms
- Dose escalation error: If symptoms are uncontrolled on one medication, the solution is switching to a different therapeutic approach (e.g., Advair to Trelegy for triple therapy), not adding medications
Bottom Line
Using Trelegy and Advair together represents inappropriate polypharmacy with duplicated drug classes, exponentially increasing adverse effect risk while providing zero additional benefit. Select the single most appropriate inhaler based on disease state (COPD vs. asthma), exacerbation history, and adherence considerations, then discontinue all other ICS/LABA-containing inhalers.